

# *Candida albicans* Biofilms and Human Disease

Clarissa J. Nobile<sup>1</sup> and Alexander D. Johnson<sup>2</sup>

<sup>1</sup>Department of Molecular and Cell Biology, School of Natural Sciences, University of California, Merced, California 95343; email: cnobile@ucmerced.edu

<sup>2</sup>Department of Microbiology and Immunology, University of California, San Francisco, California 94143; email: ajohnson@cgl.ucsf.edu

Annu. Rev. Microbiol. 2015. 69:71–92

The *Annual Review of Microbiology* is online at [micro.annualreviews.org](http://micro.annualreviews.org)

This article's doi:

10.1146/annurev-micro-091014-104330

Copyright © 2015 by Annual Reviews.  
All rights reserved

## Keywords

fungi, pathogen, microbiota, microbial community, infection, transcriptional regulation

## Abstract

In humans, microbial cells (including bacteria, archaea, and fungi) greatly outnumber host cells. *Candida albicans* is the most prevalent fungal species of the human microbiota; this species asymptotically colonizes many areas of the body, particularly the gastrointestinal and genitourinary tracts of healthy individuals. Alterations in host immunity, stress, resident microbiota, and other factors can lead to *C. albicans* overgrowth, causing a wide range of infections, from superficial mucosal to hematogenously disseminated candidiasis. To date, most studies of *C. albicans* have been carried out in suspension cultures; however, the medical impact of *C. albicans* (like that of many other microorganisms) depends on its ability to thrive as a biofilm, a closely packed community of cells. Biofilms are notorious for forming on implanted medical devices, including catheters, pacemakers, dentures, and prosthetic joints, which provide a surface and sanctuary for biofilm growth. *C. albicans* biofilms are intrinsically resistant to conventional antifungal therapeutics, the host immune system, and other environmental perturbations, making biofilm-based infections a significant clinical challenge. Here, we review our current knowledge of biofilms formed by *C. albicans* and closely related fungal species.

## Contents

|   |    |
|---|----|
| INTRODUCTION .....  | 72 |
| IN VITRO AND IN VIVO DEVELOPMENT OF <i>C. ALBICANS</i> BIOFILMS .....                       | 73 |
| GENETICS OF <i>C. ALBICANS</i> BIOFILM FORMATION .....                                      | 75 |
| Regulatory Control of <i>C. albicans</i> Biofilm Development .....                          | 75 |
| Adherence .....   | 78 |
| Hyphae .....  | 78 |
| Extracellular Matrix .....  | 78 |
| Dispersal .....   | 78 |
| Drug Resistance and the Extracellular Matrix .....  | 79 |
| Persister Cells .....   | 80 |
| BIOFILM FORMATION BY OTHER ASCOMYCOTA SPECIES .....   | 80 |
| MULTISPECIES BIOFILMS WITH <i>C. ALBICANS</i> .....   | 82 |
| PERSPECTIVES FOR DEVELOPING THERAPEUTICS<br>FOR <i>C. ALBICANS</i> BIOFILM INFECTIONS ..... | 83 |

## INTRODUCTION

Biofilms are the predominant growth state of many microorganisms. Over the last 20 years, the definition of biofilm has evolved from a stringent set of specific criteria to a broader description of microbial community structures observed in both natural and laboratory environments. In the most general sense, a biofilm is a community of adherent cells with properties that are distinct from those of free-floating (planktonic) cells (91, 92, 111). Although biofilms are often attached to solid surfaces, they can also form in other environments, for example, liquid-air interfaces. A near-universal characteristic of biofilms, compared with their free-floating counterparts, is the greater resistance of their cells to chemical and physical insults (31, 32).

It is now recognized that, for many microorganisms, the biofilm state is probably more relevant to their “natural” settings than to suspension cultures. To name just a few, these settings include aquatic environments (e.g., intertidal sediments that are home to cyanobacteria biofilms), artificial structures (e.g., pipelines where algal biofilms flourish), biomaterials (e.g., implanted heart valves where *Staphylococcus epidermidis* biofilms develop), plant tissues (e.g., root legumes colonized by rhizobia biofilms), and mammalian tissues (where *Candida albicans* biofilms are frequently found). Local effects of biofilms on their environments and/or hosts are complex; they may be favorable, harmful, or benign, and these effects can change over time. The National Institutes of Health estimate that biofilms are responsible, in one way or another, for over 80% of all microbial infections in the United States (61). In this review, we focus on *C. albicans* biofilms, which colonize implanted medical devices and mucosal surfaces, from which they can seed systemic infections in humans (46, 47, 64, 89, 97, 161, 172).


*C. albicans* is one of the very few fungal species causing disease in humans—millions of others do not. It is a member of the healthy microbiota, asymptotically colonizing the gastrointestinal (GI) tract, reproductive tract, oral cavity, and skin of most humans (1, 64, 87, 97, 99). In individuals with healthy immune systems, *C. albicans* is often harmless, kept in balance with other members of the local microbiota. However, alterations in the host microbiota (e.g., due to antibiotics), changes in the host immune response (e.g., during stress, infection by another

microbe, or immunosuppressant therapy), or variations in the local environment (e.g., shifts in pH or nutritional content) can enable *C. albicans* to overgrow and cause infection. These infections range from superficial mucosal and dermal infections, such as thrush, vaginal yeast infections, and diaper rash, to hematogenously disseminated infection with sizable mortality rates (approaching 40% in some cases) (21, 148, 202). *Candida* infections are especially serious in immunocompromised individuals (such as those with AIDS or those undergoing anticancer or immunosuppression therapies) and healthy people with implanted medical devices (96, 201).

*C. albicans* produces highly structured biofilms composed of multiple cell types (i.e., round, budding yeast-form cells; oval pseudohyphal cells; and elongated, cylindrical hyphal cells) encased in an extracellular matrix (23, 61, 158, 161). Accounting for 15% of all hospital-acquired sepsis cases, species within the CTG clade (predominantly *C. albicans*, but including several closely related species as well) are the fourth most frequent cause of bloodstream infections in clinical settings and are the predominant fungal species isolated from medical device infections (43, 152, 202, 204). Urinary and central venous catheters, pacemakers, mechanical heart valves, joint prostheses, contact lenses, and dentures are all susceptible to *C. albicans* biofilms (22, 45, 90, 175). Once it forms on an implanted medical device, a *Candida* biofilm has the potential to seed disseminated bloodstream infections and to lead to invasive systemic infections of tissues and organs. Over five million central venous catheters are placed each year in the United States (data obtained from 1992 to 2001) (90, 129). Currently—even with recently improved clinical approaches—biofilm infection occurs in over 50% of these catheters. Responsible for an estimated 100,000 deaths and \$6.5 billion in excess expenditure annually in the United States alone, these infections have serious health and economic consequences. Because fungal biofilms are largely resistant to current antifungal drugs, high antifungal doses together with removal of the colonized medical device are generally required to treat infections (6, 29, 104, 112, 121). Removal of some devices (e.g., artificial heart valves and joints) is costly and, in some cases, dangerous, and administration of high doses of antifungal agents (typically given intravascularly) can cause complications, including kidney and liver damage. Oftentimes, these treatments are not possible, as many critically ill patients are unable to tolerate them.

## IN VITRO AND IN VIVO DEVELOPMENT OF *C. ALBICANS* BIOFILMS

*C. albicans* biofilm formation in the laboratory can be readily observed on a solid surface, for example, on silicone, the common material used for intravascular catheters. Typically, a small silicone square is added to a culture of *C. albicans* (in any of a wide variety of growth media). An initial incubation is performed to allow the *C. albicans* cells to adhere to the silicone square; nonadherent cells are then washed away, and a biofilm is allowed to form. Throughout the process, the cells are constantly shaken to prevent settling; alternatively, a continuous flow of liquid across the biofilm can be imposed, mimicking exposure of an implanted catheter to blood flows. A mature biofilm typically forms within 24 hours and can be visualized by the unaided eye as a cloudy surface structure on top of the silicone square and with a microscope as an organized collection of different cell types. *C. albicans* biofilm formation comprises four temporal stages (10, 23, 47, 75, 142, 194) (**Figure 1**): (a) adherence to a surface (spherical yeast cells), (b) proliferation to form a basal layer of anchoring cells, (c) growth of pseudohyphae (ellipsoid cells joined end to end) and hyphae (chains of cylindrical cells) concomitant with production of extracellular matrix material, and (d) slow dispersal of yeast-form cells from the biofilm to seed new sites. In the laboratory, *C. albicans* biofilms can develop on several substrates and in many types of media, indicating an inherent robustness of biofilm development to changes in external conditions.



**Figure 1**

Stages of *Candida albicans* biofilm formation. ① Adherence of yeast-form cells to a surface. ② Initiation of cell proliferation, forming a basal layer of anchoring cells. ③ Maturation, including growth of hyphae concomitant with the production of extracellular matrix material. ④ Dispersal of yeast-form cells from the biofilm to seed new sites.

In vitro biofilm formation has, for the most part, correlated well with in vivo and ex vivo biofilm models. For example, *Candida* biofilms obtained from patients with denture stomatitis and from patients with infected intravascular catheters confirm the presence of yeast, hyphae and extracellular matrix (114, 162). Biofilm architectures in rat and rabbit central venous and indwelling urinary catheter models and in rat denture stomatitis models also include numerous yeast cells in the basal region, and hyphae and extracellular matrix extending throughout the biofilm (5, 84, 131, 134, 166, 173, 199). Vaginal mucosal mouse models, both in vivo (live mice inoculated with *C. albicans* on the vaginal mucosa) and ex vivo (vaginae excised from euthanized mice and then inoculated with *C. albicans* in tissue culture plates), show similar biofilm architectures, with clear yeast, hyphae, and extracellular matrix evident throughout the biofilms formed on top of the mucosal layers (72). Other animal models for monitoring biofilm formation include rodent oral mucosal, oropharyngeal, subcutaneous, and burn wound models (28, 44, 53, 166). Development of newer systems is under way to visualize the temporal and spatial progression of biofilm infections in live animals using bioluminescence imaging. For example, a vulvovaginal candidiasis model using a codon-optimized *C. albicans* luciferase bioreporter was used to observe biofilm formation in real time in the vaginal lumen (48). Other *C. albicans* bioluminescent biofilm models include oropharyngeal, cutaneous, subcutaneous, and implanted catheter models (52, 124, 153, 197, 198).

## GENETICS OF *C. ALBICANS* BIOFILM FORMATION

Although *C. albicans* is not genetically tractable in the conventional sense (its parasexual cycle is cumbersome to use in the lab), its genome is relatively simple to alter using recombinant DNA technologies. For example, nearly 1,000 gene knockout mutants of this diploid organism have been constructed (out of ~6,000 genes total), and many of these deletion mutants have been screened for biofilm formation. Other approaches include genome-wide transcriptional profiling and proteomics techniques to identify genes and proteins expressed specifically in biofilms (115, 191, 209). These studies have revealed that many hundreds of mRNAs and proteins are differentially expressed between biofilms and planktonic cells.

In this section we review these genetic studies with particular emphasis on the master regulators that orchestrate biofilm formation as well as some of the important nonregulatory genes that have been genetically validated to play important roles in biofilm formation. We exclude genes whose deletions cause broad phenotypes (such as slow growth), as their effects on biofilm formation are likely to be indirect. Because the available deletion libraries are enriched for knockouts of transcriptional regulators, we probably know more about the transcriptional regulation of biofilm production than we do about the process itself. Based on the current literature, we count 50 transcriptional regulators (**Table 1**) and 101 nonregulatory genes (**Table 2**) that have functionally validated roles in biofilm formation.

### Regulatory Control of *C. albicans* Biofilm Development

In 2012, a large transcriptional network that controls the development of *C. albicans* biofilms was described (140). This network consists of six master transcriptional regulators (Efg1, Tec1, Bcr1, Ndt80, Brg1, and Rob1), each of which is required for biofilm development in both in vitro and in vivo rat catheter and rat denture models (140). Each master regulator also controls the expression of the other master regulators, resulting in a complex, intertwined regulatory network. Together, these six master regulators directly bind to the promoters of and very likely regulate the expression of approximately 1,000 target genes, some of which are additional transcriptional regulators. Work carried out in both planktonic and biofilm conditions has indicated that various target genes play roles in hyphal formation, adhesion, drug resistance, and matrix production (see 61 for a summary), all of which are important characteristics of biofilms. However, the majority of newly identified target genes in the biofilm network have not yet been studied; many have no overt sequence similarity to any previously characterized genes from any organism. Orthology mapping indicates that the entire set of target genes is significantly enriched for “young” genes, suggesting that the ability of *C. albicans* to form biofilms evolved relatively recently with respect to evolutionary timescales. This inference provides an explanation as to why *C. albicans* and closely related species are only a few of the many fungal species able to form biofilms within a mammalian host. With the outline of the biofilm network (which is undoubtedly incomplete), it is now possible to systematically study the role of the nonregulatory target genes in biofilm development.

In addition to the 6 master transcriptional regulators discussed above, another 44 transcriptional regulators have been identified; if any of these is deleted, some aspect of *C. albicans* biofilm formation is affected under at least one condition (**Table 1**; revised from 61 and 18). The majority of these regulators are directly bound by at least one of the 6 master biofilm network regulators, indicating that they have direct regulatory connections to the core biofilm circuit (**Table 1**).

The transcriptional network controlling biofilm development in *C. albicans* may seem overly complex, but it is typical of many other transcriptional networks, particularly those in eukaryotic organisms. For example, mammalian stem cell maintenance, *Drosophila* eye development, and

**Table 1** *C. albicans* transcriptional regulators with roles in biofilm formation

| ORF No.           | Name          | Biofilm phenotype <sup>a</sup> |           | Integrated in core network? <sup>b</sup> | Reference(s) |
|-------------------|---------------|--------------------------------|-----------|--|--------------|
|                   |               | In vitro                       | In vivo   |  |              |
| <i>orf19.6124</i> | <i>ACE2</i>   | Defective                      | Defective | No                                       | 57, 86       |
| <i>orf19.2331</i> | <i>ADA2</i>   | Defective                      | NA        | No                                       | 57           |
| <i>orf19.7381</i> | <i>AHR1</i>   | Defective                      | NA        | Yes                                      | 8            |
| <i>orf19.4766</i> | <i>ARG81</i>  | Defective                      | NA        | No                                       | 57           |
| <i>orf19.723</i>  | <i>BCR1</i>   | Defective                      | Defective | Yes                                      | 140, 141     |
| <i>orf19.6874</i> | <i>BPR1</i>   | Defective                      | NA        | Yes                                      | 59           |
| <i>orf19.4056</i> | <i>BRG1</i>   | Defective                      | Defective | Yes                                      | 140          |
| <i>orf19.4670</i> | <i>CAS5</i>   | Defective                      | NA        | Yes                                      | 57           |
| <i>orf19.2356</i> | <i>CRZ2</i>   | No effect                      | Defective | Yes                                      | 57           |
| <i>orf19.3127</i> | <i>CZF1</i>   | Defective                      | NA        | Yes                                      | 57           |
| <i>orf19.3252</i> | <i>DAL81</i>  | Defective                      | NA        | No                                       | 57           |
| <i>orf19.610</i>  | <i>EFG1</i>   | Defective                      | Defective | Yes                                      | 140, 163     |
| <i>orf19.3193</i> | <i>FCR3</i>   | Defective                      | NA        | Yes                                      | 57           |
| <i>orf19.6680</i> | <i>FGR27</i>  | Defective                      | NA        | No                                       | 57           |
| <i>orf19.1093</i> | <i>FLO8</i>   | Defective                      | Defective | Yes                                      | 59           |
| <i>orf19.5338</i> | <i>GAL4</i>   | Enhanced                       | Enhanced  | Yes                                      | 59           |
| <i>orf19.1358</i> | <i>GCN4</i>   | Defective                      | NA        | Yes                                      | 66           |
| <i>orf19.2842</i> | <i>GZF3</i>   | Defective                      | NA        | Yes                                      | 59           |
| <i>orf19.4225</i> | <i>LEU3</i>   | Defective                      | NA        | No                                       | 57           |
| <i>orf19.5312</i> | <i>MET4</i>   | Defective                      | NA        | No                                       | 57           |
| <i>orf19.6309</i> | <i>MSS11</i>  | Defective                      | NA        | Yes                                      | 193          |
| <i>orf19.2119</i> | <i>NDT80</i>  | Defective                      | Defective | Yes                                      | 140, 178     |
| <i>orf19.2012</i> | <i>NOT3</i>   | Defective                      | NA        | No                                       | 57           |
| <i>orf19.7150</i> | <i>NRG1</i>   | Defective                      | NA        | Yes                                      | 195          |
| <i>orf19.7247</i> | <i>RIM101</i> | Defective                      | No effect | Yes                                      | 59           |
| <i>orf19.2823</i> | <i>RFG1</i>   | Defective                      | No effect | Yes                                      | 59           |
| <i>orf19.4590</i> | <i>RFX2</i>   | Enhanced                       | Enhanced  | Yes                                      | 59           |
| <i>orf19.4662</i> | <i>RLM1</i>   | Defective                      | Defective | No                                       | 136          |
| <i>orf19.4998</i> | <i>ROB1</i>   | Defective                      | Defective | Yes                                      | 140          |
| <i>orf19.5871</i> | <i>SNF5</i>   | Defective                      | Defective | No                                       | 57           |
| <i>orf19.7319</i> | <i>SUC1</i>   | Defective                      | NA        | No                                       | 57           |
| <i>orf19.798</i>  | <i>TAF14</i>  | Defective                      | NA        | No                                       | 57           |
| <i>orf19.5908</i> | <i>TEC1</i>   | Defective                      | Defective | Yes                                      | 140, 141     |
| <i>orf19.4062</i> | <i>TRY2</i>   | Defective                      | NA        | No                                       | 57           |
| <i>orf19.1971</i> | <i>TRY3</i>   | Defective                      | NA        | No                                       | 57           |
| <i>orf19.5975</i> | <i>TRY4</i>   | Defective                      | NA        | Yes                                      | 57           |
| <i>orf19.3434</i> | <i>TRY5</i>   | Defective                      | NA        | Yes                                      | 57           |
| <i>orf19.6824</i> | <i>TRY6</i>   | Defective                      | NA        | Yes                                      | 57           |
| <i>orf19.4941</i> | <i>TYE7</i>   | Defective                      | NA        | Yes                                      | 17           |
| <i>orf19.7317</i> | <i>UGA33</i>  | Defective                      | NA        | No                                       | 57           |
| <i>orf19.1822</i> | <i>UME6</i>   | Defective                      | NA        | Yes                                      | 194, 195     |

(Continued)

**Table 1 (Continued)**

| ORF No.           | Name         | Biofilm phenotype <sup>a</sup> |           | Integrated in core network: <sup>b</sup> | Reference(s) |
|-------------------|--------------|--------------------------------|-----------|--|--------------|
|                   |              | In vitro                       | In vivo   |  |              |
| <i>orf19.1035</i> | <i>WAR1</i>  | Defective                      | NA        | No                                       | 57           |
| <i>orf19.3794</i> | <i>ZAP1</i>  | Enhanced                       | Enhanced  | Yes                                      | 57, 63, 144  |
| <i>orf19.1718</i> | <i>ZCF8</i>  | Defective                      | NA        | Yes                                      | 57           |
| <i>orf19.4767</i> | <i>ZCF28</i> | No effect                      | Defective | No                                       | 57           |
| <i>orf19.5924</i> | <i>ZCF31</i> | Defective                      | NA        | Yes                                      | 57           |
| <i>orf19.6182</i> | <i>ZCF34</i> | Defective                      | NA        | No                                       | 57           |
| <i>orf19.7583</i> | <i>ZCF39</i> | Defective                      | NA        | No                                       | 57           |
| <i>orf19.6781</i> | <i>ZFU2</i>  | No effect                      | Defective | No                                       | 57           |
| <i>orf19.3187</i> | <i>ZNC1</i>  | Defective                      | NA        | No                                       | 57           |

Abbreviations: NA, not available; ORF, open reading frame.

<sup>a</sup>Indicates biofilm-related phenotype of mutation, where mutation can cause a defect or an enhancement.

<sup>b</sup>Indicates that the gene is bound by any of the six “master” biofilm regulators (140).

*Arabidopsis* circadian clock rhythms are all controlled by multiple transcriptional regulators that regulate each other and many additional target genes (3, 110, 203, 206). Complex transcriptional circuits also control pseudohyphal growth and the response to osmotic stress in baker’s yeast (19, 137) as well as the white-opaque cell-type switch in *C. albicans* (76). Although its significance in any transcriptional network is not fully understood, this high degree of complexity does seem to be a common feature of networks that coordinate morphological changes. In the following sections, we combine genetic results with genomic analyses and break down the biofilm circuit into smaller pieces, each of which contributes to biofilm formation and maintenance.

**Table 2 *C. albicans* nonregulatory genes with roles in biofilm formation**

| Biofilm process         | Genes   | References   |
|-------------------------|---|--|
| Adhesion                | <i>ALS1, ALS2, ALS3, ALS5, EAP1, ECM33, HWP1, MP65, MSB2, PBR1, PGA1, PGA7, PGA10, PGA13, PGA26, PSA2</i>   | 65, 74, 102, 106, 138, 150, 155, 168, 170, 171, 177, 183, 213  |
| Filamentation/cell wall | <i>AMS1, CAS4, CBK1, CHK1, CSA1, DSE1, GAL10, GAL102, GWT1, HGC1, HWP2, HYR1, KEM1, KIC1, MDS3, MED20, MFG1, MKC1, MOB2, NOT4, PMT1, PMT2, PMT4, PMT6, RBT1, RBT5, RHR2, SM11, SPF1, SPT20, SUN41, SUR7, TPK1, TPK2, YAK1</i>                               | 15, 37, 41, 49, 51, 55, 67, 68, 71, 93, 94, 98, 107, 136, 146, 149, 150, 165, 169, 177, 179, 182, 190, 196, 200, 208 |
| Drug resistance         | <i>CDR1, CDR2, MDR1, QDR1, QDR2, QDR3</i>   | 119, 126, 180  |
| Extracellular matrix    | <i>ADH1, ADH5, BGL2, CSH1, GCA1, GCA2, GSC1, IFD6, PHR1, XOG1</i>   | 7, 127, 144, 189   |
| Dispersion              | <i>HOS2, HSP90, PES1, SET3, SIF2, SNT1, YWPI</i>  | 70, 139, 167, 177, 194   |
| Unknown                 | <i>AQY1, CAT2, GUP1, HSP21, HSP104, IPT1, NDH51, NUP85, OBP<sub>a</sub>, OBP<sub>alpha</sub>, ORF19.2175, ORF19.5412, PAPI, PAP<sub>alpha</sub>, PDX1, PIK<sub>a</sub>, PIK<sub>alpha</sub>, RIX7, SHA3, SOH1, SRB9, SSN3, SUV3, VAM3, VPS1, VPS4, YVC1</i> | 14, 56, 58, 83, 103, 108, 109, 120, 146, 147, 165, 177, 184, 186, 188, 192, 196, 207                                 |

## Adherence

The ability of cells in a biofilm to adhere to each other and to surfaces, which can be hard (a medical device) or soft (a mucosal layer), is important for all stages of *C. albicans* biofilm development. For example, the biofilm master regulator Bcr1 and some of its downstream targets, including the cell wall proteins Als1, Als3, and Hwp1, are all required for adherence during biofilm formation (23, 138, 141, 143, 145, 212). Many additional transcriptional regulators have been implicated in adherence (49, 57, 123, 143, 212; **Table 1**), the majority having been discovered in a study that screened a library of transcriptional regulator mutants using an in vitro flow cell assay (57). Here, 30 transcriptional regulators were identified as important for adherence to a silicone substrate under these conditions. Of these 30, 4 (Bcr1, Ace2, Snf5, and Arg81) were also required for biofilm formation under common conditions (shaking in microtiter plates) for in vitro biofilm formation. It is clear that biofilm formation by *C. albicans* can occur over a broad range of conditions and that the genetic requirements likely vary from one condition to the next.

## Hyphae

*C. albicans* is distinguished from many other fungal species by its ability to form both yeast cells and hyphae under many different environmental conditions. (This is the basis of the early classification of *C. albicans* as dimorphic.) Although they readily form in planktonic cultures, hyphae are an important structural component of *C. albicans* biofilms; thus, it is not surprising that genes required for hyphal growth in suspension cultures are also necessary for proper biofilm formation. These include the transcriptional regulators Efg1, Tec1, Ndt80, and Rob1 (140, 163, 174). The hyphae in biofilms contribute to the overall architectural stability of the biofilm, acting as a support scaffold for yeast cells and other hyphae. Thus, the ability to form hyphae and the ability of these hyphae to adhere to one another and to yeast cells are critical for normal biofilm development and maintenance. Indeed, the master regulator Bcr1 is not needed for hyphal formation per se, but it is needed for the hyphae to adhere to one another in biofilms (141).

## Extracellular Matrix

Mature *C. albicans* biofilms are encased in a complex material known as the extracellular matrix. Two known transcriptional regulators of biofilm matrix production in *C. albicans* are Rlm1 and Zap1. Deletion of *RLM1* causes a reduction in matrix levels (136), whereas deletion of *ZAP1* leads to an increase in the accumulation of extracellular matrix material, probably by upregulating the glucoamylases Gca1 and Gca2 (144).

## Dispersal

Dispersal of cells within a *C. albicans* biofilm into the environment is another important stage in the biofilm life cycle. Cells are dispersed continuously throughout biofilm formation, and they are thought to be primarily (if not exclusively) in the round yeast form (194). Although dispersed cells morphologically resemble yeast cells in the planktonic mode of growth, they have distinct characteristics. These include (relative to planktonic cells) increased adherence properties, the ability to form biofilms more efficiently, and enhanced virulence in mouse models of infection (194). Two transcriptional regulators of *C. albicans* biofilm dispersal have been identified, Nrg1 and Ume6; transcriptional overexpression of either regulator increased the number of dispersed cells actively released from the biofilm (194, 195). Nrg1 probably acts

through a Set3 chromatin-modifying complex (77, 139). Indeed, mutant strains of individual Set3 complex members formed extra strong biofilms that were incapable of normal biofilm dispersal and especially recalcitrant to mechanical perturbation (139). Nrg1 and Set3 complex mutants are hyperfilamentous, consistent with their inability to generate yeast-form cells (77, 195).

The molecular chaperone Hsp90 has also been implicated in *C. albicans* biofilm dispersal, as depletion of Hsp90 markedly reduces the number of dispersed cells from a biofilm (167). Depletion of Hsp90 also induces filamentation by relieving Hsp90-mediated repression of the cAMP-PKA signaling pathway (181). The cell wall protein Ywp1 is also important for biofilm dispersal, as deletion of *YWP1* leads to decreased biofilm dispersal and increased biofilm adhesiveness (69, 70). It is possible that any mutation that favors filamentous cells over yeast-form cells reduces biofilm dispersal. Thus, both types of cells are required for fully functioning biofilms.

## Drug Resistance and the Extracellular Matrix

The inherent resistance of *C. albicans* biofilms to antimicrobial agents is a key feature of the biofilm mode of growth. This resistance is due to the upregulation of efflux pumps, the presence of the extracellular matrix, and the presence of recalcitrant persister cells. In *C. albicans*, two major classes of efflux pumps modulate drug exportation: the ATP-binding cassette transporter superfamily (including *CDR1* and *CDR2*) and the major facilitator class (including *MDR1*) (4, 33, 156). In planktonic cells, these efflux pumps are typically upregulated in response to antifungal drugs; in biofilms, however, they become upregulated within the first few hours of surface contact and remain upregulated throughout biofilm development, whether or not an antifungal drug is present (119, 126, 133, 140, 156, 205). This seemingly automatic upregulation of efflux pumps clearly contributes to the recalcitrance of biofilms to treatment with antifungal agents; it may be a manifestation of small-molecule warfare between *C. albicans* and other microbial species that occupy the same environmental niches.

Secreted extracellular matrix also contributes to biofilm drug resistance, both acting as a physical barrier to drug penetration and directly contributing to the overall structural integrity of the biofilm (2, 11, 130, 135). One known constituent of the biofilm matrix that contributes to its drug-resistance properties is the polysaccharide  $\beta$ -1,3-glucan (130). Thus, treatment of biofilms with  $\beta$ -1,3-glucanase increases the susceptibility of biofilms to fluconazole (130), and addition of exogenous  $\beta$ -1,3-glucans increases the tolerance of planktonic cells to fluconazole (122). Genes involved in production and delivery of  $\beta$ -1,3-glucans include the synthase-encoding gene *FKS1* and the genes *BGL2*, *XOG1*, and *PHR1*, which encode proteins involved in the modification and transport of  $\beta$ -glucans (132, 189). The transcriptional regulator Rlm1 (discussed above) contributes to antifungal drug resistance by regulating the expression of *FKS1* (136). Finally, extracellular DNA is also a component of the matrix in *C. albicans* and contributes, probably indirectly, to drug resistance (117). For example, one study reported that treatment of biofilms with DNase enhanced the activity of caspofungin and amphotericin B in disrupting mature *C. albicans* biofilms (116).

Understanding how the matrix contributes to drug resistance in *C. albicans* has been challenging, in part because of difficulties in identifying the key matrix constituents. Significant progress has been made in comprehensive analysis of its macromolecular content (209). The *C. albicans* biofilm matrix is predominantly composed of proteins and glycoproteins (55%), carbohydrates (25%), lipids (15%), and nucleic acids (5%). Over 500 proteins were identified in the matrix. Most of these were predicted to be enzymes, including hydrolyzing enzymes, suggesting that the matrix may play an active role in breaking down biopolymers. It is intriguing to consider the biofilm matrix as an extracellular, enzymatically active element of a *C. albicans* biofilm—one that can break down molecules both as a protective response and to access a nutrient source. Polysaccharides

make up the second major fraction of the matrix, consisting largely of mannan-glucan complexes made predominantly of  $\alpha$ -1,6-linked mannan and  $\alpha$ -1,2-linked side chains complexed to  $\beta$ -1,6-glucan (209). Thus, although  $\beta$ -1,3-glucans contribute to drug resistance and are the major cell wall polysaccharide (130), we now know that they constitute only a small fraction of the total polysaccharides present, implying that the matrix is not constructed simply of released cell wall constituents.

### Persister Cells

Persister cells are another contributor to the drug-resistance properties of biofilms. A minor subset of metabolically dormant yeast cells that stochastically arise as phenotypical variants within biofilms, persister cells are extremely resistant to antifungal drugs (100). Although we know little about the formation and roles of persister cells in *C. albicans* biofilms, we do know that the drug resistance of persister cells is independent of cell membrane composition and efflux pump expression; rather, it is the result of the metabolically dormant state of the cells (88, 100). We know little about how persister cells are regulated and controlled, despite their importance to the drug resistance of *C. albicans* biofilms.

### BIOFILM FORMATION BY OTHER ASCOMYCOTA SPECIES

As mentioned, *C. albicans* is not the only fungal species that can form biofilms in a mammalian host. The closely related species *Candida dubliniensis*, *Candida parapsilosis*, *Candida tropicalis*, and *Candida krusei* have all been implicated in biofilm-associated infections (73, 157, 187). Each of these species can form a biofilm in vitro, but the thickness, strength, and robustness in different environmental conditions decrease as species diverge phylogenetically away from *C. albicans*. Thus, among the CTG clade, *C. albicans* is probably the best biofilm former in the sense that it can form relatively thick biofilms under many different environmental conditions. It is also the most extensively studied.

Outside the CTG clade, numerous fungal species have been reported to form biofilms in vitro and in vivo. It should be emphasized that biofilm formation is often loosely defined; in some cases, simply adhering to plastic or glass is considered a sufficient criterion. The type of biofilm formed by *C. albicans* is probably unique to the CTG clade; given that the *C. albicans* biofilm circuit is a recent evolutionary innovation, it is likely that biofilms from more distantly related fungal species were also relatively recent innovations that independently evolved along those clades. Thus, it is unlikely that biofilms from fungal species hundreds of millions of years distant from *C. albicans* are similar in detail. Below, we briefly survey the literature on biofilm formation outside of the CTG clade.

*C. albicans* is a member of the phylum Ascomycota, which includes the genera *Acremonium*, *Aspergillus*, *Blastomyces*, *Blastoschizomyces*, *Candida*, *Cladosporium*, *Coccidioides*, *Fusarium*, *Histoplasma*, *Paracoccidioides*, *Pneumocystis*, *Saccharomyces* and *Scedosporium*. For some of these genera, biofilm formation has been implicated in pathogenesis in humans, but for others this connection is less clear. For example, a number of these biofilm formers (**Table 3**) have been tested for drug susceptibility in vitro, and cells in biofilms have been found to be more resistant to drugs compared with cells grown in suspension culture. These include (in addition to *Candida*) members from *Acremonium*, *Aspergillus*, *Cladosporium*, *Fusarium*, and *Pneumocystis* (9, 20, 35, 42, 79, 160, 176). *Candida glabrata* (which, despite the name, lies well outside the CTG clade phylogenetically) forms thin biofilms in vitro (without hyphal cells) on biotic and abiotic surfaces associated with the human host (157).

**Table 3 Non-*C. albicans* biofilm formers in the Ascomycota phylum**

| Species                            | Reference(s)     |
|------------------------------------|------------------|
| <i>Candida dubliniensis</i>        | 73, 157, 187     |
| <i>Candida parapsilosis</i>        | 73, 157          |
| <i>Candida tropicalis</i>          | 73, 157          |
| <i>Candida krusei</i>              | 73, 157          |
| <i>Candida glabrata</i>            | 95, 157          |
| <i>Acremonium implicatum</i>       | 211              |
| <i>Aspergillus fumigatus</i>       | 125, 158, 176    |
| <i>Blastoschizomyces capitatus</i> | 16, 38, 39       |
| <i>Cladosporium sphaerospermum</i> | 211              |
| <i>Coccidioides immitis</i>        | 40               |
| <i>Fusarium solani</i>             | 211              |
| <i>Histoplasma capsulatum</i>      | 154              |
| <i>Pneumocystis jirovecii</i>      | 35, 36           |
| <i>Saccharomyces cerevisiae</i>    | 26, 50, 128, 164 |
| <i>Scedosporium prolificans</i>    | 30               |

*Saccharomyces cerevisiae*, or baker's yeast, rarely causes infections in humans and is generally not considered a pathogen. In a few case studies, however, *S. cerevisiae* has been implicated in catheter-associated infections with mixed-species biofilms in patients in intensive care units (ICUs), and it is able to form a thin biofilm consisting of round, budding yeast-form cells and pseudohyphal cells in vitro (26, 50, 128, 164). *Blastoschizomyces capitatus* is another rare cause of infection in humans, although more cases have been emerging in highly immunocompromised patients in ICUs. *B. capitatus* can cause catheter-associated bloodstream infections and has the capacity to form a biofilm both in vitro and in vivo (16, 38).

*Aspergillus* is a fungal pathogen of great medical importance that can form biofilms both in vitro and in vivo (125, 159). *Aspergillus fumigatus* is a common invasive colonizer of the respiratory tract in individuals with cystic fibrosis or other conditions that compromise the immune system (176). During infection, airborne spores enter the host via the airway and undergo a morphological switch to the filamentous growth form upon contact with host tissues. *A. fumigatus* then continues to proliferate along the lining of the respiratory tract, forming a dense network of hyphal cells. Aspergillomas, or dense hyphal balls, may also form as *A. fumigatus* continues to proliferate in the respiratory tract; these structures share many architectural characteristics with biofilms formed by other fungal species (159).

Other Ascomycota members also infect the respiratory tract of mammals. For example, *Pneumocystis jirovecii* causes frequently fatal pneumonia in mammals. Morphological examination of lung tissue infected by *P. jirovecii* reveals a biofilm-like growth structure consisting of round yeast-form clusters that can be recapitulated in vitro under certain laboratory conditions (35, 36). *Scedosporium prolificans*, a recently emerging human fungal pathogen of the respiratory system, may also form biofilms, given that fungus balls, resembling biofilm structures, have been observed in some clinical cases (30). *Histoplasma capsulatum* is another opportunistic pathogen that infects the respiratory system of mammals, causing histoplasmosis (85). *H. capsulatum* typically exists in a filamentous form in the environment outside of the host but is usually found as yeast-form cells within the host. There is at least one report of *H. capsulatum* forming biofilms consisting of dense clusters of yeast-form cells in vitro, suggesting that *H. capsulatum* may exist in biofilms in vivo

(154). Along with *H. capsulatum*, *Coccidioides immitis*, *Paracoccidioides brasiliensis*, and *Blastomyces dermatitidis* are all sources of mycoses in immunocompromised individuals and have also caused endemic outbreaks in specific geographical regions (62, 113). All infect the respiratory system but are capable of causing invasive infections. Although rare, *C. immitis* has been reported to form biofilms on medical devices (40). Whether *B. dermatitidis* and *P. brasiliensis* form biofilms in vitro or in vivo is unknown.

Finally, the ascomycete species *Fusarium solani*, *Acremonium implicatum*, and *Cladosporium sphaerospermum* can cause keratitis in mammals, a serious infection of the cornea of the eye, as well as other less-common infections. Keratitis is generally thought of as a biofilm infection and has been associated with the use of contact lenses. In fact, a *Fusarium* keratitis outbreak occurred in the United States as a result of a contact lens multipurpose solution lacking sufficient antifungal efficacy against *F. solani* (24, 105). Recent work in vitro has shown that *F. solani*, *A. implicatum*, and *C. sphaerospermum* can all form biofilms under laboratory conditions (211). Though biofilm formation has been most extensively studied for *C. albicans*, it is clear—even from this brief discussion—that biofilm formation by an evolutionarily broad range of fungal species has enormous impact on human health.

## MULTISPECIES BIOFILMS WITH *C. ALBICANS*

Microbial infections are often thought of, and treated, as if a single microbial species were acting alone. Yet they occur in the presence of the human microbiota—the collection of microbes that inhabit the body. This microbiota includes members from three major branches of life: bacteria, archaea, and fungi. Outnumbering human cells by at least a factor of ten, these microbes form a complex ecosystem, one whose balance can be affected by the host's diet, genetic background, and alterations in immunity and by transient environmental perturbations, such as changes in pH, viscosity of mucosal layers, and the use of broad-spectrum antibiotics. Thus, expanding our understanding of biofilm formation in the context of other microbial members is an important goal. Although *C. albicans* is the fungal pathogen most frequently isolated from human infections, other *Candida* species have been found together with *C. albicans* in polymicrobial biofilms from patients (27). These species include *C. dubliniensis*, *C. tropicalis*, *C. parapsilosis*, *C. guilliermondii*, *C. krusei*, and *C. glabrata* (80, 90, 118, 151). We know virtually nothing about the interactions among these *Candida* species in polymicrobial biofilms.

However, limited progress has been made in understanding the dual-species biofilms *C. albicans* forms with a few common bacterial species likely to interact with it in humans. Several studies have investigated such dual-species biofilms comprising *C. albicans* and a bacterium commonly isolated from denture stomatitis, periodontitis, or dental caries, such as *Streptococcus mutans*, *Streptococcus gordonii*, *Actinomyces viscosus*, or *Fusobacterium* species (12, 81, 82). *C. albicans* also interacts with several bacterial species found in the gut, such as *Enterococcus* and *Escherichia* species; those found in the vagina, such as *Lactobacillus* species; and those found in the lungs of patients with cystic fibrosis, such as *Pseudomonas aeruginosa* (13, 34, 54, 78). From these studies, we have learned that *C. albicans* and bacteria can interact with each other by secretion of signaling molecules that influence the behavior of one species toward the other, by direct cell-cell physical contact, and by alterations of the local environment that influence the other species (e.g., alterations in pH and oxygen concentrations). For example, *P. aeruginosa* secretes a 12-carbon acyl homoserine lactone that modulates hyphal growth by *C. albicans* (78). Another study examined dual-species biofilms *C. albicans* forms with one of five prevalent members of the human gut microbiota: *Bacteroides fragilis*, *Clostridium perfringens*, *Escherichia coli*, *Klebsiella pneumoniae*, or *Enterococcus faecalis* (60). In this study, biofilms formed by *C. albicans* provided a hypoxic microenvironment that could support

the growth of the two strictly anaerobic bacteria, *B. fragilis* and *C. perfringens*—even though the biofilms were grown under oxygen-rich conditions. Thus, a *C. albicans* biofilm can act as a safe haven for anaerobic pathogens in oxygen-rich environments. Moreover, when cultured together with *C. albicans* in ambient oxygen, these anaerobes could induce the latter to form mini-biofilms, which, in turn, could protect the bacteria and allow them to proliferate under otherwise toxic conditions. Interactions occurring between different species in polymicrobial biofilms and their relevance to human health are clearly of great interest and importance.

## PERSPECTIVES FOR DEVELOPING THERAPEUTICS FOR *C. ALBICANS* BIOFILM INFECTIONS

No biofilm-specific drugs exist today for *C. albicans* (or any microbe), making treatment of biofilm-based infections particularly problematic. However, a better understanding of the molecular mechanisms underlying biofilm formation and maintenance could lead to the development of new antifungals that specifically target the biofilm state. For example, identification of the molecular mechanisms behind biofilm dispersal could lead to a drug-based strategy that prevents it—or enhances it to the extent that a stable biofilm cannot form. A better understanding of adherence—both between *C. albicans* cells and a surface and between cells within the biofilm—could lead to strategies to prevent biofilm formation or to disrupt mature biofilms. Finally, a better understanding of the molecular basis of metabolic dormancy of subpopulations of cells, such as persister cells, might lead to strategies to reverse the physiology of these cells. These are only a few of the possible mechanism-based strategies that could be exploited to develop new biofilm-specific therapeutics.

Screens of chemical libraries have identified compounds that disrupt formation and/or maintenance of biofilms (25, 101, 185, 210). Although results from this approach are encouraging, it remains to be seen whether it will lead to useful therapeutics. Finally, any strategies that weaken *C. albicans* biofilm formation or maintenance could render biofilms susceptible to conventional antifungal drugs, making combination therapies effective, at least in principle. Current antifungal drugs have only two specific targets (ergosterol biosynthesis and 1,3- $\beta$ -D-glucan synthesis), and it is widely believed that antifungal drugs with new mechanisms of action are needed (4, 18, 79). Our developing mechanistic knowledge of both the biofilm and the planktonic states (as well as the transition between the two) will hopefully be translated into new therapies to effectively clear biofilm-based infections and reduce relapse infection rates.

## DISCLOSURE STATEMENT

The authors are not aware of any affiliations, memberships, funding, or financial holdings that might be perceived as affecting the objectivity of this review.

## ACKNOWLEDGMENTS

We thank Nairi Hartooni for drawing **Figure 1**. This study is supported by National Institutes of Health grants R00AI100896 and R01AI083311.

## LITERATURE CITED

1. Achkar JM, Fries BC. 2010. *Candida* infections of the genitourinary tract. *Clin. Microbiol. Rev.* 23:253–73
2. Al-Fattani MA, Douglas LJ. 2006. Biofilm matrix of *Candida albicans* and *Candida tropicalis*: chemical composition and role in drug resistance. *J. Med. Microbiol.* 55:999–1008

3. Alabadi D, Oyama T, Yanovsky MJ, Harmon FG, Mas P, Kay SA. 2001. Reciprocal regulation between TOC1 and LHY/CCA1 within the *Arabidopsis* circadian clock. *Science* 293:880–83
4. Anderson JB. 2005. Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. *Nat. Rev. Microbiol.* 3:547–56
5. Andes D, Nett J, Oschel P, Albrecht R, Marchillo K, Pitula A. 2004. Development and characterization of an in vivo central venous catheter *Candida albicans* biofilm model. *Infect. Immun.* 72:6023–31
6. Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, et al. 2012. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. *Clin. Infect. Dis.* 54:1110–22
7. Angiolella L, Stringaro AR, De Bernardis F, Posteraro B, Bonito M, et al. 2008. Increase of virulence and its phenotypic traits in drug-resistant strains of *Candida albicans*. *Antimicrob. Agents Chemother.* 52:927–36
8. Askew C, Sellam A, Epp E, Mallick J, Hogues H, et al. 2011. The zinc cluster transcription factor Ahr1p directs Mcm1p regulation of *Candida albicans* adhesion. *Mol. Microbiol.* 79:940–53
9. Bachmann SP, VandeWalle K, Ramage G, Patterson TF, Wickes BL, et al. 2002. In vitro activity of caspofungin against *Candida albicans* biofilms. *Antimicrob. Agents Chemother.* 46:3591–96
10. Baillie GS, Douglas LJ. 1999. Role of dimorphism in the development of *Candida albicans* biofilms. *J. Med. Microbiol.* 48:671–79
11. Baillie GS, Douglas LJ. 2000. Matrix polymers of *Candida* biofilms and their possible role in biofilm resistance to antifungal agents. *J. Antimicrob. Chemother.* 46:397–403
12. Bamford CV, d’Mello A, Nobbs AH, Dutton LC, Vickerman MM, Jenkinson HF. 2009. *Streptococcus gordonii* modulates *Candida albicans* biofilm formation through intergeneric communication. *Infect. Immun.* 77:3696–704
13. Bandara HM, Yau JY, Watt RM, Jin LJ, Samaranyake LP. 2009. *Escherichia coli* and its lipopolysaccharide modulate in vitro *Candida* biofilm formation. *J. Med. Microbiol.* 58:1623–31
14. Bernardo SM, Khalique Z, Kot J, Jones JK, Lee SA. 2008. *Candida albicans* VPS1 contributes to protease secretion, filamentation, and biofilm formation. *Fungal Genet. Biol.* 45:861–77
15. Bernardo SM, Lee SA. 2010. *Candida albicans* SUR7 contributes to secretion, biofilm formation, and macrophage killing. *BMC Microbiol.* 10:133
16. Birrenbach T, Bertschy S, Aebersold F, Mueller NJ, Achermann Y, et al. 2012. Emergence of *Blas-toschizomyces capitatus* yeast infections, Central Europe. *Emerg. Infect. Dis.* 18:98–101
17. Bonhomme J, Chauvel M, Goyard S, Roux P, Rossignol T, d’Enfert C. 2011. Contribution of the glycolytic flux and hypoxia adaptation to efficient biofilm formation by *Candida albicans*. *Mol. Microbiol.* 80:995–1013
18. Bonhomme J, d’Enfert C. 2013. *Candida albicans* biofilms: building a heterogeneous, drug-tolerant environment. *Curr. Opin. Microbiol.* 16:398–403
19. Borneman AR, Leigh-Bell JA, Yu H, Bertone P, Gerstein M, Snyder M. 2006. Target hub proteins serve as master regulators of development in yeast. *Genes Dev.* 20:435–48
20. Bowyer P, Moore CB, Rautema R, Denning DW, Richardson MD. 2011. Azole antifungal resistance today: focus on *Aspergillus*. *Curr. Infect. Dis. Rep.* 13:485–91
21. Calderone RA, Fonzi WA. 2001. Virulence factors of *Candida albicans*. *Trends Microbiol.* 9:327–35
22. Cauda R. 2009. Candidaemia in patients with an inserted medical device. *Drugs* 69(Suppl. 1):33–38
23. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. 2001. Biofilm formation by the fungal pathogen *Candida albicans*: development, architecture, and drug resistance. *J. Bacteriol.* 183:5385–94
24. Chang DC, Grant GB, O’Donnell K, Wannemuehler KA, Noble-Wang J, et al. 2006. Multistate outbreak of *Fusarium keratitis* associated with use of a contact lens solution. *JAMA* 296:953–63
25. Chavez-Dozal AA, Jahng M, Rane HS, Asare K, Kulkarny VV, et al. 2014. In vitro analysis of flufenamic acid activity against *Candida albicans* biofilms. *Int. J. Antimicrob. Agents* 43:86–91
26. Chitasombat MN, Kofteridis DP, Jiang Y, Tarrand J, Lewis RE, Kontoyiannis DP. 2012. Rare opportunistic (non-*Candida*, non-*Cryptococcus*) yeast bloodstream infections in patients with cancer. *J. Infect.* 64:68–75
27. Chitnis AS, Magill SS, Edwards JR, Chiller TM, Fridkin SK, Lessa FC. 2012. Trends in *Candida* central line-associated bloodstream infections among NICUs, 1999–2009. *Pediatrics* 130:e46–52

28. Cole MF, Bowen WH, Zhao XJ, Cihlar RL. 1995. Avirulence of *Candida albicans* auxotrophic mutants in a rat model of oropharyngeal candidiasis. *FEMS Microbiol. Lett.* 126:177–80
29. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, et al. 2012. ESCMID guideline for the diagnosis and management of *Candida* diseases 2012: non-neutropenic adult patients. *Clin. Microbiol. Infect.* 18(Suppl. 7):19–37
30. Cortez KJ, Roilides E, Quiroz-Telles F, Meletiadis J, Antachopoulos C, et al. 2008. Infections caused by *Scedosporium* spp. *Clin. Microbiol. Rev.* 21:157–97
31. Costerton JW, Cheng KJ, Geesey GG, Ladd TI, Nickel JC, et al. 1987. Bacterial biofilms in nature and disease. *Annu. Rev. Microbiol.* 41:435–64
32. Costerton JW, Stewart PS, Greenberg EP. 1999. Bacterial biofilms: a common cause of persistent infections. *Science* 284:1318–22
33. Cowen LE. 2008. The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype. *Nat. Rev. Microbiol.* 6:187–98
34. Cruz MR, Graham CE, Gagliano BC, Lorenz MC, Garsin DA. 2013. *Enterococcus faecalis* inhibits hyphal morphogenesis and virulence of *Candida albicans*. *Infect. Immun.* 81:189–200
35. Cushion MT, Collins MS. 2011. Susceptibility of *Pneumocystis* to echinocandins in suspension and biofilm cultures. *Antimicrob. Agents Chemother.* 55:4513–18
36. Cushion MT, Collins MS, Linke MJ. 2009. Biofilm formation by *Pneumocystis* spp. *Eukaryot. Cell* 8:197–206
37. Daher JY, Koussa J, Younes S, Khalaf RA. 2011. The *Candida albicans* Dse1 protein is essential and plays a role in cell wall rigidity, biofilm formation, and virulence. *Interdiscip. Perspect. Infect. Dis.* 2011:504280
38. D'Antonio D, Mazzoni A, Iacone A, Violante B, Capuani MA, et al. 1996. Emergence of fluconazole-resistant strains of *Blastoschizomyces capitatus* causing nosocomial infections in cancer patients. *J. Clin. Microbiol.* 34:753–55
39. D'Antonio D, Parruti G, Pontieri E, Di Bonaventura G, Manzoli L, et al. 2004. Slime production by clinical isolates of *Blastoschizomyces capitatus* from patients with hematological malignancies and catheter-related fungemia. *Eur. J. Clin. Microbiol. Infect.* 23:787–89
40. Davis LE, Cook G, Costerton JW. 2002. Biofilm on ventriculo-peritoneal shunt tubing as a cause of treatment failure in coccidioidal meningitis. *Emerg. Infect. Dis.* 8:376–79
41. Desai JV, Bruno VM, Ganguly S, Stamper RJ, Mitchell KF, et al. 2013. Regulatory role of glycerol in *Candida albicans* biofilm formation. *mBio* 4:e00637–12
42. Desai JV, Mitchell AP, Andes DR. 2014. Fungal biofilms, drug resistance, and recurrent infection. *Cold Spring Harb. Perspect. Med.* 4:a019729
43. Dominic RM, Shenoy S, Baliga S. 2007. *Candida* biofilms in medical devices: evolving trends. *Kathmandu Univ. Med. J.* 5:431–36
44. Dongari-Bagtzoglou A, Kashleva H, Dwivedi P, Diaz P, Vasilakos J. 2009. Characterization of mucosal *Candida albicans* biofilms. *PLOS ONE* 4:e7967
45. Donlan RM, Costerton JW. 2002. Biofilms: survival mechanisms of clinically relevant microorganisms. *Clin. Microbiol. Rev.* 15:167–93
46. Douglas LJ. 2002. Medical importance of biofilms in *Candida* infections. *Rev. Iberoamericana Micol.* 19:139–43
47. Douglas LJ. 2003. *Candida* biofilms and their role in infection. *Trends Microbiol.* 11:30–36
48. Doyle TC, Nawotka KA, Kawahara CB, Francis KP, Contag PR. 2006. Visualizing fungal infections in living mice using bioluminescent pathogenic *Candida albicans* strains transformed with the firefly luciferase gene. *Microb. Pathog.* 40:82–90
49. Dwivedi P, Thompson A, Xie Z, Kashleva H, Ganguly S, et al. 2011. Role of Bcr1-activated genes Hwp1 and Hyr1 in *Candida albicans* oral mucosal biofilms and neutrophil evasion. *PLOS ONE* 6:e16218
50. Enache-Angoulvant A, Hennequin C. 2005. Invasive *Saccharomyces* infection: a comprehensive review. *Clin. Infect. Dis.* 41:1559–68
51. Ene IV, Bennett RJ. 2009. Hwp1 and related adhesins contribute to both mating and biofilm formation in *Candida albicans*. *Eukaryot. Cell* 8:1909–13

52. Enjalbert B, Rachini A, Vedyappan G, Pietrella D, Spaccapelo R, et al. 2009. A multifunctional, synthetic *Gaussia princeps* luciferase reporter for live imaging of *Candida albicans* infections. *Infect. Immun.* 77:4847–58
53. Fader RC, Nunez D, Unbehagen J, Linares HA. 1985. Experimental candidiasis after thermal injury. *Infect. Immun.* 49:780–84
54. Falagas ME, Betsi GI, Athanasiou S. 2006. Probiotics for prevention of recurrent vulvovaginal candidiasis: a review. *J. Antimicrob. Chemother.* 58:266–72
55. Fanning S, Xu W, Beaurepaire C, Suhan JP, Nantel A, Mitchell AP. 2012. Functional control of the *Candida albicans* cell wall by catalytic protein kinase A subunit Tpk1. *Mol. Microbiol.* 86:284–302
56. Ferreira C, Silva S, Faria-Oliveira F, Pinho E, Henriques M, Lucas C. 2010. *Candida albicans* virulence and drug-resistance requires the *O*-acyltransferase Gup1p. *BMC Microbiol.* 10:238
57. Finkel JS, Xu W, Huang D, Hill EM, Desai JV, et al. 2012. Portrait of *Candida albicans* adherence regulators. *PLOS Pathog.* 8:e1002525
58. Fiori A, Kucharikova S, Govaert G, Cammue BP, Thevissen K, Van Dijck P. 2012. The heat-induced molecular disaggregase Hsp104 of *Candida albicans* plays a role in biofilm formation and pathogenicity in a worm infection model. *Eukaryot. Cell* 11:1012–20
59. Fox EP, Bui CK, Nett JE, Hartooni N, Mui MM, et al. 2015. An expanded regulatory network temporally controls *Candida albicans* biofilm formation. *Mol. Microbiol.* 96:1226–39
60. Fox EP, Cowley ES, Nobile CJ, Hartooni N, Newman DK, Johnson AD. 2014. Anaerobic bacteria grow within *Candida albicans* biofilms and induce biofilm formation in suspension cultures. *Curr. Biol.* 24:2411–16
61. Fox EP, Nobile CJ. 2012. A sticky situation: untangling the transcriptional network controlling biofilm development in *Candida albicans*. *Transcription* 3:315–22
62. Fridkin SK, Jarvis WR. 1996. Epidemiology of nosocomial fungal infections. *Clin. Microbiol. Rev.* 9:499–511
63. Ganguly S, Bishop AC, Xu W, Ghosh S, Nickerson KW, et al. 2011. Zap1 control of cell-cell signaling in *Candida albicans* biofilms. *Eukaryot. Cell* 10:1448–54
64. Ganguly S, Mitchell AP. 2011. Mucosal biofilms of *Candida albicans*. *Curr. Opin. Microbiol.* 14:380–85
65. Garcia MC, Lee JT, Ramsook CB, Alsteens D, Dufrene YF, Lipke PN. 2011. A role for amyloid in cell aggregation and biofilm formation. *PLOS ONE* 6:e17632
66. Garcia-Sanchez S, Aubert S, Iraqui I, Janbon G, Ghigo JM, d'Enfert C. 2004. *Candida albicans* biofilms: a developmental state associated with specific and stable gene expression patterns. *Eukaryot. Cell* 3:536–45
67. Giacometti R, Kronberg F, Biondi RM, Passeron S. 2011. *Candida albicans* Tpk1p and Tpk2p isoforms differentially regulate pseudohyphal development, biofilm structure, cell aggregation and adhesins expression. *Yeast* 28:293–308
68. Goyard S, Knechtel P, Chauvel M, Mallet A, Prevost MC, et al. 2008. The Yak1 kinase is involved in the initiation and maintenance of hyphal growth in *Candida albicans*. *Mol. Biol. Cell* 19:2251–66
69. Granger BL. 2012. Insight into the antiadhesive effect of yeast wall protein 1 of *Candida albicans*. *Eukaryot. Cell* 11:795–805
70. Granger BL, Flenniken ML, Davis DA, Mitchell AP, Cutler JE. 2005. Yeast wall protein 1 of *Candida albicans*. *Microbiology* 151:1631–44
71. Gutierrez-Escribano P, Zeidler U, Suarez MB, Bachellier-Bassi S, Clemente-Blanco A, et al. 2012. The NDR/LATS kinase Cbk1 controls the activity of the transcriptional regulator Bcr1 during biofilm formation in *Candida albicans*. *PLOS Pathog.* 8:e1002683
72. Harriott MM, Lilly EA, Rodriguez TE, Fidel PL Jr, Noverr MC. 2010. *Candida albicans* forms biofilms on the vaginal mucosa. *Microbiology* 156:3635–44
73. Hasan F, Xess I, Wang X, Jain N, Fries BC. 2009. Biofilm formation in clinical *Candida* isolates and its association with virulence. *Microbes Infect.* 11:753–61
74. Hashash R, Younes S, Bahnan W, El Koussa J, Maalouf K, et al. 2011. Characterisation of Pga1, a putative *Candida albicans* cell wall protein necessary for proper adhesion and biofilm formation. *Mycoses* 54:491–500
75. Hawser SP, Douglas LJ. 1994. Biofilm formation by *Candida* species on the surface of catheter materials in vitro. *Infect. Immun.* 62:915–21

76. Hernday AD, Lohse MB, Fordyce PM, Nobile CJ, Derisi JL, Johnson AD. 2013. Structure of the transcriptional network controlling white-opaque switching in *Candida albicans*. *Mol. Microbiol.* 90:22–35
77. Hnisz D, Bardet AF, Nobile CJ, Petryshyn A, Glaser W, et al. 2012. A histone deacetylase adjusts transcription kinetics at coding sequences during *Candida albicans* morphogenesis. *PLoS Genet.* 8:e1003118
78. Hogan DA, Vik A, Kolter R. 2004. A *Pseudomonas aeruginosa* quorum-sensing molecule influences *Candida albicans* morphology. *Mol. Microbiol.* 54:1212–23
79. Jabra-Rizk MA, Falkler WA, Meiller TF. 2004. Fungal biofilms and drug resistance. *Emerg. Infect. Dis.* 10:14–19
80. Jabra-Rizk MA, Falkler WA Jr, Merz WG, Baqui AA, Kelley JL, Meiller TF. 2000. Retrospective identification and characterization of *Candida dubliniensis* isolates among *Candida albicans* clinical laboratory isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected individuals. *J. Clin. Microbiol.* 38:2423–26
81. Jack AA, Daniels DE, Jepson MA, Vickerman MM, Lamont RJ, et al. 2014. The *Streptococcus gordonii* comCDE (competence) operon modulates biofilm formation with *Candida albicans*. *Microbiology* 161:411–21
82. Jarosz LM, Deng DM, van der Mei HC, Crielaard W, Krom BP. 2009. *Streptococcus mutans* competence-stimulating peptide inhibits *Candida albicans* hypha formation. *Eukaryot. Cell* 8:1658–64
83. Johnson C, Kweon HK, Sheidy D, Shively CA, Mellacheruvu D, et al. 2014. The yeast Sks1p kinase signaling network regulates pseudohyphal growth and glucose response. *PLoS Genet.* 10:e1004183
84. Johnson CC, Yu A, Lee H, Fidel PL Jr, Noverr MC. 2012. Development of a contemporary animal model of *Candida albicans*-associated denture stomatitis using a novel intraoral denture system. *Infect. Immun.* 80:1736–43
85. Kauffman CA. 2007. Histoplasmosis: a clinical and laboratory update. *Clin. Microbiol. Rev.* 20:115–32
86. Kelly MT, MacCallum DM, Clancy SD, Odds FC, Brown AJ, Butler G. 2004. The *Candida albicans* CaACE2 gene affects morphogenesis, adherence and virulence. *Mol. Microbiol.* 53:969–83
87. Kennedy MJ, Volz PA. 1985. Ecology of *Candida albicans* gut colonization: inhibition of *Candida* adhesion, colonization, and dissemination from the gastrointestinal tract by bacterial antagonism. *Infect. Immun.* 49:654–63
88. Khot PD, Suci PA, Miller RL, Nelson RD, Tyler BJ. 2006. A small subpopulation of blastospores in *Candida albicans* biofilms exhibit resistance to amphoterin B associated with differential regulation of ergosterol and beta-1,6-glucan pathway genes. *Antimicrob. Agents Chemother.* 50:3708–16
89. Kim J, Sudbery P. 2011. *Candida albicans*, a major human fungal pathogen. *J. Microbiol.* 49:171–77
90. Kojic EM, Darouiche RO. 2004. *Candida* infections of medical devices. *Clin. Microbiol. Rev.* 17:255–67
91. Kolter R. 2010. Biofilms in lab and nature: a molecular geneticist's voyage to microbial ecology. *Int. Microbiol.* 13:1–7
92. Kolter R, Greenberg EP. 2006. Microbial sciences: the superficial life of microbes. *Nature* 441:300–2
93. Krueger KE, Ghosh AK, Krom BP, Cihlar RL. 2004. Deletion of the NOT4 gene impairs hyphal development and pathogenicity in *Candida albicans*. *Microbiology* 150:229–40
94. Kruppa M, Krom BP, Chauhan N, Bambach AV, Cihlar RL, Calderone RA. 2004. The two-component signal transduction protein Chk1p regulates quorum sensing in *Candida albicans*. *Eukaryot. Cell* 3:1062–65
95. Kucharikova S, Tournu H, Lagrou K, Van Dijck P, Bujdakova H. 2011. Detailed comparison of *Candida albicans* and *Candida glabrata* biofilms under different conditions and their susceptibility to caspofungin and anidulafungin. *J. Med. Microbiol.* 60:1261–69
96. Kullberg BJ, Oude Lashof AM. 2002. Epidemiology of opportunistic invasive mycoses. *Eur. J. Med. Res.* 7:183–91
97. Kumamoto CA. 2002. *Candida* biofilms. *Curr. Opin. Microbiol.* 5:608–11
98. Kumamoto CA. 2005. A contact-activated kinase signals *Candida albicans* invasive growth and biofilm development. *PNAS* 102:5576–81
99. Kumamoto CA. 2011. Inflammation and gastrointestinal *Candida* colonization. *Curr. Opin. Microbiol.* 14:386–91
100. LaFleur MD, Kumamoto CA, Lewis K. 2006. *Candida albicans* biofilms produce antifungal-tolerant persister cells. *Antimicrob. Agents Chemother.* 50:3839–46

101. LaFleur MD, Lucumi E, Napper AD, Diamond SL, Lewis K. 2011. Novel high-throughput screen against *Candida albicans* identifies antifungal potentiators and agents effective against biofilms. *J. Antimicrob. Chemother.* 66:820–26
102. Laforet L, Moreno I, Sanchez-Fresneda R, Martinez-Esparza M, Martinez JP, et al. 2011. Pga26 mediates filamentation and biofilm formation and is required for virulence in *Candida albicans*. *FEMS Yeast Res.* 11:389–97
103. Lattif AA, Mukherjee PK, Chandra J, Roth MR, Welti R, et al. 2011. Lipidomics of *Candida albicans* biofilms reveals phase-dependent production of phospholipid molecular classes and role for lipid rafts in biofilm formation. *Microbiology* 157:3232–42
104. Lepak A, Andes D. 2011. Fungal sepsis: optimizing antifungal therapy in the critical care setting. *Crit. Care Clin.* 27:123–47
105. Levy B, Heiler D, Norton S. 2006. Report on testing from an investigation of *Fusarium* keratitis in contact lens wearers. *Eye Contact Lens* 32:256–61
106. Li F, Svarovsky MJ, Karlsson AJ, Wagner JP, Marchillo K, et al. 2007. Eap1p, an adhesin that mediates *Candida albicans* biofilm formation in vitro and in vivo. *Eukaryot. Cell* 6:931–39
107. Lin CH, Kabrawala S, Fox EP, Nobile CJ, Johnson AD, Bennett RJ. 2013. Genetic control of conventional and pheromone-stimulated biofilm formation in *Candida albicans*. *PLoS Pathog.* 9:e1003305
108. Lindsay AK, Morales DK, Liu Z, Grahl N, Zhang A, et al. 2014. Analysis of *Candida albicans* mutants defective in the Cdk8 module of Mediator reveal links between metabolism and biofilm formation. *PLoS Genet.* 10:e1004567
109. Liu G, Vellucci VF, Kyc S, Hostetter MK. 2009. Simvastatin inhibits *Candida albicans* biofilm in vitro. *Pediatr. Res.* 66:600–4
110. Locke JC, Southern MM, Kozma-Bognar L, Hibberd V, Brown PE, et al. 2005. Extension of a genetic network model by iterative experimentation and mathematical analysis. *Mol. Syst. Biol.* 1:2005.0013
111. Lopez D, Vlamakis H, Kolter R. 2010. Biofilms. *Cold Spring Harb. Perspect. Biol.* 2:a000398
112. Lortholary O, Petrikos G, Akova M, Arendrup MC, Arian-Akdagli S, et al. 2012. ESCMID guideline for the diagnosis and management of *Candida* diseases 2012: patients with HIV infection or AIDS. *Clin. Microbiol. Infect.* 18(Suppl. 7):68–77
113. Marques SA. 2012. Paracoccidioidomycosis. *Clin. Dermatol.* 30:610–15
114. Marrie TJ, Costerton JW. 1984. Scanning and transmission electron microscopy of in situ bacterial colonization of intravenous and intraarterial catheters. *J. Clin. Microbiol.* 19:687–93
115. Martinez-Gomariz M, Perumal P, Mekala S, Nombela C, Chaffin WL, Gil C. 2009. Proteomic analysis of cytoplasmic and surface proteins from yeast cells, hyphae, and biofilms of *Candida albicans*. *Proteomics* 9:2230–52
116. Martins M, Henriques M, Lopez-Ribot JL, Oliveira R. 2012. Addition of DNase improves the in vitro activity of antifungal drugs against *Candida albicans* biofilms. *Mycoses* 55:80–85
117. Martins M, Uppuluri P, Thomas DP, Cleary IA, Henriques M, et al. 2010. Presence of extracellular DNA in the *Candida albicans* biofilm matrix and its contribution to biofilms. *Mycopathologia* 169:323–31
118. Masala L, Luzzati R, Maccacaro L, Antozzi L, Concia E, Fontana R. 2003. Nosocomial cluster of *Candida guilliermondii* fungemia in surgical patients. *Eur. J. Clin. Microbiol. Infect. Dis.* 22:686–88
119. Mateus C, Crow SA Jr, Ahearn DG. 2004. Adherence of *Candida albicans* to silicone induces immediate enhanced tolerance to fluconazole. *Antimicrob. Agents Chemother.* 48:3358–66
120. Melo AS, Padovan AC, Serafim RC, Puzer L, Carmona AK, et al. 2006. The *Candida albicans* AAA ATPase homologue of *Saccharomyces cerevisiae* Rix7p (YLL034c) is essential for proper morphology, biofilm formation and activity of secreted aspartyl proteinases. *Genet. Mol. Res.* 5:664–87
121. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, et al. 2009. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. *Clin. Infect. Dis.* 49:1–45
122. Mitchell KF, Taff HT, Cuevas MA, Reinicke EL, Sanchez H, Andes DR. 2013. Role of matrix  $\beta$ -1,3 glucan in antifungal resistance of non-*albicans* *Candida* biofilms. *Antimicrob. Agents Chemother.* 57:1918–20
123. Monnot C, Boisrame A, Da Costa G, Chauvel M, Sautour M, et al. 2013. Rbt1 protein domains analysis in *Candida albicans* brings insights into hyphal surface modifications and Rbt1 potential role during adhesion and biofilm formation. *PLoS ONE* 8:e82395

124. Mosci P, Pericolini E, Gabrielli E, Kenno S, Perito S, et al. 2013. A novel bioluminescence mouse model for monitoring oropharyngeal candidiasis in mice. *Virulence* 4:250–54
125. Mowat E, Butcher J, Lang S, Williams C, Ramage G. 2007. Development of a simple model for studying the effects of antifungal agents on multicellular communities of *Aspergillus fumigatus*. *J. Med. Microbiol.* 56:1205–12
126. Mukherjee PK, Chandra J, Kuhn DM, Ghannoum MA. 2003. Mechanism of fluconazole resistance in *Candida albicans* biofilms: phase-specific role of efflux pumps and membrane sterols. *Infect. Immun.* 71:4333–40
127. Mukherjee PK, Mohamed S, Chandra J, Kuhn D, Liu S, et al. 2006. Alcohol dehydrogenase restricts the ability of the pathogen *Candida albicans* to form a biofilm on catheter surfaces through an ethanol-based mechanism. *Infect. Immun.* 74:3804–16
128. Munoz P, Bouza E, Cuenca-Estrella M, Eiros JM, Perez MJ, et al. 2005. *Saccharomyces cerevisiae* fungemia: an emerging infectious disease. *Clin. Infect. Dis.* 40:1625–34
129. Natl. Nosocom. Infect. Surveill. Sys. 2001. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992–June 2001, issued August 2001. *Am. J. Infect. Control.* 29:404–21
130. Nett J, Lincoln L, Marchillo K, Massey R, Holoyda K, et al. 2007. Putative role of beta-1,3 glucans in *Candida albicans* biofilm resistance. *Antimicrob. Agents Chemother.* 51:510–20
131. Nett JE, Brooks EG, Cabezas-Olcoz J, Sanchez H, Zarnowski R, et al. 2014. Rat indwelling urinary catheter model of *Candida albicans* biofilm infection. *Infect. Immun.* 82:4931–40
132. Nett JE, Crawford K, Marchillo K, Andes DR. 2010. Role of Fks1p and matrix glucan in *Candida albicans* biofilm resistance to an echinocandin, pyrimidine, and polyene. *Antimicrob. Agents Chemother.* 54:3505–8
133. Nett JE, Lepak AJ, Marchillo K, Andes DR. 2009. Time course global gene expression analysis of an in vivo *Candida* biofilm. *J. Infect. Dis.* 200:307–13
134. Nett JE, Marchillo K, Spiegel CA, Andes DR. 2010. Development and validation of an in vivo *Candida albicans* biofilm denture model. *Infect. Immun.* 78:3650–59
135. Nett JE, Sanchez H, Cain MT, Andes DR. 2010. Genetic basis of *Candida* biofilm resistance due to drug-sequestering matrix glucan. *J. Infect. Dis.* 202:171–75
136. Nett JE, Sanchez H, Cain MT, Ross KM, Andes DR. 2011. Interface of *Candida albicans* biofilm matrix-associated drug resistance and cell wall integrity regulation. *Eukaryot. Cell* 10:1660–69
137. Ni L, Bruce C, Hart C, Leigh-Bell J, Gelperin D, et al. 2009. Dynamic and complex transcription factor binding during an inducible response in yeast. *Genes Dev.* 23:1351–63
138. Nobile CJ, Andes DR, Nett JE, Smith FJ, Yue F, et al. 2006. Critical role of Bcr1-dependent adhesins in *C. albicans* biofilm formation in vitro and in vivo. *PLoS Pathog.* 2:e63
139. Nobile CJ, Fox EP, Hartooni N, Mitchell KF, Hnisz D, et al. 2014. A histone deacetylase complex mediates biofilm dispersal and drug resistance in *Candida albicans*. *mBio* 5:e01201–14
140. Nobile CJ, Fox EP, Nett JE, Sorrells TR, Mitrovich QM, et al. 2012. A recently evolved transcriptional network controls biofilm development in *Candida albicans*. *Cell* 148:126–38
141. Nobile CJ, Mitchell AP. 2005. Regulation of cell-surface genes and biofilm formation by the *C. albicans* transcription factor Bcr1p. *Curr. Biol.* 15:1150–55
142. Nobile CJ, Mitchell AP. 2006. Genetics and genomics of *Candida albicans* biofilm formation. *Cell. Microbiol.* 8:1382–91
143. Nobile CJ, Nett JE, Andes DR, Mitchell AP. 2006. Function of *Candida albicans* adhesin Hwp1 in biofilm formation. *Eukaryot. Cell* 5:1604–10
144. Nobile CJ, Nett JE, Hernday AD, Homann OR, Deneault JS, et al. 2009. Biofilm matrix regulation by *Candida albicans* Zap1. *PLOS Biol.* 7:e1000133
145. Nobile CJ, Schneider HA, Nett JE, Sheppard DC, Filler SG, et al. 2008. Complementary adhesion function in *C. albicans* biofilm formation. *Curr. Biol.* 18:1017–24
146. Norice CT, Smith FJ Jr, Solis N, Filler SG, Mitchell AP. 2007. Requirement for *Candida albicans* Sun41 in biofilm formation and virulence. *Eukaryot. Cell* 6:2046–55
147. Palanisamy SK, Ramirez MA, Lorenz M, Lee SA. 2010. *Candida albicans* PEP12 is required for biofilm integrity and in vivo virulence. *Eukaryot. Cell* 9:266–77
148. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, et al. 2004. Guidelines for treatment of candidiasis. *Clin. Infect. Dis.* 38:161–89

149. Peltroche-Llacsahuanga H, Goyard S, d'Enfert C, Prill SK, Ernst JF. 2006. Protein O-mannosyltransferase isoforms regulate biofilm formation in *Candida albicans*. *Antimicrob. Agents Chemother.* 50:3488–91
150. Perez A, Pedros B, Murgui A, Casanova M, Lopez-Ribot JL, Martinez JP. 2006. Biofilm formation by *Candida albicans* mutants for genes coding fungal proteins exhibiting the eight-cysteine-containing CFEM domain. *FEMS Yeast Res.* 6:1074–84
151. Perlroth J, Choi B, Spellberg B. 2007. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. *Med. Mycol.* 45:321–46
152. Pfaller MA, Diekema DJ. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. *Clin. Microbiol. Rev.* 20:133–63
153. Pietrella D, Enjalbert B, Zeidler U, Znaidi S, Rachini A, et al. 2012. A luciferase reporter for gene expression studies and dynamic imaging of superficial *Candida albicans* infections. *Methods Mol. Biol.* 845:537–46
154. Pitangui NS, Sardi JC, Silva JF, Benaducci T, Moraes da Silva RA, et al. 2012. Adhesion of *Histoplasma capsulatum* to pneumocytes and biofilm formation on an abiotic surface. *Biofouling* 28:711–18
155. Puri S, Kumar R, Chadha S, Tati S, Conti HR, et al. 2012. Secreted aspartic protease cleavage of *Candida albicans* Msb2 activates Cek1 MAPK signaling affecting biofilm formation and oropharyngeal candidiasis. *PLOS ONE* 7:e46020
156. Ramage G, Bachmann S, Patterson TF, Wickes BL, Lopez-Ribot JL. 2002. Investigation of multidrug efflux pumps in relation to fluconazole resistance in *Candida albicans* biofilms. *J. Antimicrob. Chemother.* 49:973–80
157. Ramage G, Martinez JP, Lopez-Ribot JL. 2006. *Candida* biofilms on implanted biomaterials: a clinically significant problem. *FEMS Yeast Res.* 6:979–86
158. Ramage G, Mowat E, Jones B, Williams C, Lopez-Ribot J. 2009. Our current understanding of fungal biofilms. *Crit. Rev. Microbiol.* 35:340–55
159. Ramage G, Rajendran R, Gutierrez-Correa M, Jones B, Williams C. 2011. *Aspergillus* biofilms: clinical and industrial significance. *FEMS Microbiol. Lett.* 324:89–97
160. Ramage G, Rajendran R, Sherry L, Williams C. 2012. Fungal biofilm resistance. *Int. J. Microbiol.* 2012:528521
161. Ramage G, Saville SP, Thomas DP, Lopez-Ribot JL. 2005. *Candida* biofilms: an update. *Eukaryot. Cell* 4:633–38
162. Ramage G, Tomsett K, Wickes BL, Lopez-Ribot JL, Redding SW. 2004. Denture stomatitis: a role for *Candida* biofilms. *Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.* 98:53–59
163. Ramage G, VandeWalle K, Lopez-Ribot JL, Wickes BL. 2002. The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in *Candida albicans*. *FEMS Microbiol. Lett.* 214:95–100
164. Reynolds TB, Fink GR. 2001. Bakers' yeast, a model for fungal biofilm formation. *Science* 291:878–81
165. Richard ML, Nobile CJ, Bruno VM, Mitchell AP. 2005. *Candida albicans* biofilm-defective mutants. *Eukaryot. Cell* 4:1493–502
166. Rიცოვა M, Kucharikova S, Tournu H, Hendrix J, Bujdakova H, et al. 2010. *Candida albicans* biofilm formation in a new in vivo rat model. *Microbiology* 156:909–19
167. Robbins N, Uppuluri P, Nett J, Rajendran R, Ramage G, et al. 2011. Hsp90 governs dispersion and drug resistance of fungal biofilms. *PLOS Pathog.* 7:e1002257
168. Rouabhia M, Semaili A, Chandra J, Mukherjee P, Chmielewski W, Ghannoum MA. 2012. Disruption of the ECM33 gene in *Candida albicans* prevents biofilm formation, engineered human oral mucosa tissue damage and gingival cell necrosis/apoptosis. *Mediat. Inflamm.* 2012:398207
169. Ryan O, Shapiro RS, Kurat CF, Mayhew D, Baryshnikova A, et al. 2012. Global gene deletion analysis exploring yeast filamentous growth. *Science* 337:1353–56
170. Sahni N, Yi S, Daniels KJ, Srikantha T, Pujol C, Soll DR. 2009. Genes selectively up-regulated by pheromone in white cells are involved in biofilm formation in *Candida albicans*. *PLOS Pathog.* 5:e1000601
171. Sandini S, Stringaro A, Arancia S, Colone M, Mondello F, et al. 2011. The MP65 gene is required for cell wall integrity, adherence to epithelial cells and biofilm formation in *Candida albicans*. *BMC Microbiol.* 11:106

172. Sardi JC, Scorzoni L, Bernardi T, Fusco-Almeida AM, Mendes Giannini MJ. 2013. *Candida* species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. *J. Med. Microbiol.* 62:10–24
173. Schinabeck MK, Long LA, Hossain MA, Chandra J, Mukherjee PK, et al. 2004. Rabbit model of *Candida albicans* biofilm infection: liposomal amphotericin B antifungal lock therapy. *Antimicrob. Agents Chemother.* 48:1727–32
174. Schweizer A, Rupp S, Taylor BN, Rollinghoff M, Schroppel K. 2000. The TEA/ATTS transcription factor CaTec1p regulates hyphal development and virulence in *Candida albicans*. *Mol. Microbiol.* 38:435–45
175. Seddiki SM, Boucherit-Otmani Z, Boucherit K, Badsı-Amir S, Taleb M, Kunkel D. 2013. Assessment of the types of catheter infectivity caused by *Candida* species and their biofilm formation: first study in an intensive care unit in Algeria. *Int. J. Gen. Med.* 6:1–7
176. Seidler MJ, Salvenmoser S, Muller FM. 2008. *Aspergillus fumigatus* forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells. *Antimicrob. Agents Chemother.* 52:4130–36
177. Sellam A, Al-Niemi T, McInnerney K, Brumfield S, Nantel A, Suci PA. 2009. A *Candida albicans* early stage biofilm detachment event in rich medium. *BMC Microbiol.* 9:25
178. Sellam A, Askew C, Epp E, Tebbji F, Mullick A, et al. 2010. Role of transcription factor CaNdt80p in cell separation, hyphal growth, and virulence in *Candida albicans*. *Eukaryot. Cell* 9:634–44
179. Sen M, Shah B, Rakshit S, Singh V, Padmanabhan B, et al. 2011. UDP-glucose 4, 6-dehydratase activity plays an important role in maintaining cell wall integrity and virulence of *Candida albicans*. *PLOS Pathog.* 7:e1002384
180. Shah AH, Singh A, Dhamgaye S, Chauhan N, Vandeputte P, et al. 2014. Novel role of a family of major facilitator transporters in biofilm development and virulence of *Candida albicans*. *Biochem. J.* 460:223–35
181. Shapiro RS, Uppuluri P, Zaas AK, Collins C, Senn H, et al. 2009. Hsp90 orchestrates temperature-dependent *Candida albicans* morphogenesis via Ras1-PKA signaling. *Curr. Biol.* 19:621–29
182. Singh V, Sathesh SV, Raghavendra ML, Sadhale PP. 2007. The key enzyme in galactose metabolism, UDP-galactose-4-epimerase, affects cell-wall integrity and morphology in *Candida albicans* even in the absence of galactose. *Fungal Genet. Biol.* 44:563–74
183. Srikantha T, Daniels KJ, Pujol C, Kim E, Soll DR. 2013. Identification of genes upregulated by the transcription factor Bcr1 that are involved in impermeability, impenetrability, and drug resistance of *Candida albicans*  $\alpha$  biofilms. *Eukaryot. Cell* 12:875–88
184. Srikantha T, Daniels KJ, Pujol C, Sahni N, Yi S, Soll DR. 2012. Nonsex genes in the mating type locus of *Candida albicans* play roles in  $\alpha$  biofilm formation, including impermeability and fluconazole resistance. *PLOS Pathog.* 8:e1002476
185. Srinivasan A, Gupta CM, Agrawal CM, Leung KP, Lopez-Ribot JL, Ramasubramanian AK. 2014. Drug susceptibility of matrix-encapsulated *Candida albicans* nano-biofilms. *Biotechnol. Bioeng.* 111:418–24
186. Strijbis K, van Roermund CW, Visser WF, Mol EC, van den Burg J, et al. 2008. Carnitine-dependent transport of acetyl coenzyme A in *Candida albicans* is essential for growth on nonfermentable carbon sources and contributes to biofilm formation. *Eukaryot. Cell* 7:610–18
187. Sullivan DJ, Westerneng TJ, Haynes KA, Bennett DE, Coleman DC. 1995. *Candida dublimiensis* sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. *Microbiology* 141(Part 7):1507–21
188. Sun X, Lu H, Jiang Y, Cao Y. 2013. CaIPF19998 reduces drug susceptibility by enhancing the ability of biofilm formation and regulating redox homeostasis in *Candida albicans*. *Curr. Microbiol.* 67:322–26
189. Taff HT, Nett JE, Zarnowski R, Ross KM, Sanchez H, et al. 2012. A *Candida* biofilm-induced pathway for matrix glucan delivery: implications for drug resistance. *PLOS Pathog.* 8:e1002848
190. Tan X, Fuchs BB, Wang Y, Chen W, Yuen GJ, et al. 2014. The role of *Candida albicans* SPT20 in filamentation, biofilm formation and pathogenesis. *PLOS ONE* 9:e94468
191. Thomas DP, Bachmann SP, Lopez-Ribot JL. 2006. Proteomics for the analysis of the *Candida albicans* biofilm lifestyle. *Proteomics* 6:5795–804
192. Thomas DP, Lopez-Ribot JL, Lee SA. 2009. A proteomic analysis of secretory proteins of a pre-vacuolar mutant of *Candida albicans*. *J. Proteomics* 73:342–51

193. Tsai PW, Chen YT, Yang CY, Chen HF, Tan TS, et al. 2014. The role of Mss11 in *Candida albicans* biofilm formation. *Mol. Genet. Genomics* 289:807–19
194. Uppuluri P, Chaturvedi AK, Srinivasan A, Banerjee M, Ramasubramaniam AK, et al. 2010. Dispersion as an important step in the *Candida albicans* biofilm developmental cycle. *PLOS Pathog.* 6:e1000828
195. Uppuluri P, Pierce CG, Thomas DP, Bubeck SS, Saville SP, Lopez-Ribot JL. 2010. The transcriptional regulator Nrg1p controls *Candida albicans* biofilm formation and dispersion. *Eukaryot. Cell* 9:1531–37
196. Uwamahoro N, Qu Y, Jelicic B, Lo TL, Beaupaire C, et al. 2012. The functions of Mediator in *Candida albicans* support a role in shaping species-specific gene expression. *PLOS Genet.* 8:e1002613
197. Vande Velde G, Kucharikova S, Schrevens S, Himmelreich U, Van Dijck P. 2014. Towards non-invasive monitoring of pathogen-host interactions during *Candida albicans* biofilm formation using in vivo bioluminescence. *Cell. Microbiol.* 16:115–30
198. Vande Velde G, Kucharikova S, Van Dijck P, Himmelreich U. 2014. Bioluminescence imaging of fungal biofilm development in live animals. *Methods Mol. Biol.* 1098:153–67
199. Wang X, Fries BC. 2011. A murine model for catheter-associated candiduria. *J. Med. Microbiol.* 60:1523–29
200. Watanabe NA, Miyazaki M, Horii T, Sagane K, Tsukahara K, Hata K. 2012. E1210, a new broad-spectrum antifungal, suppresses *Candida albicans* hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis. *Antimicrob. Agents Chemother.* 56:960–71
201. Weig M, Gross U, Muhlschlegel F. 1998. Clinical aspects and pathogenesis of *Candida* infection. *Trends Microbiol.* 6:468–70
202. Wenzel RP. 1995. Nosocomial candidemia: risk factors and attributable mortality. *Clin. Infect. Dis.* 20:1531–34
203. Wilson NK, Foster SD, Wang X, Knezevic K, Schutte J, et al. 2010. Combinatorial transcriptional control in blood stem/progenitor cells: genome-wide analysis of ten major transcriptional regulators. *Cell Stem Cell* 7:532–44
204. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. *Clin. Infect. Dis.* 39:309–17
205. Yeater KM, Chandra J, Cheng G, Mukherjee PK, Zhao X, et al. 2007. Temporal analysis of *Candida albicans* gene expression during biofilm development. *Microbiology* 153:2373–85
206. Young RA. 2011. Control of the embryonic stem cell state. *Cell* 144:940–54
207. Yu Q, Wang F, Zhao Q, Chen J, Zhang B, et al. 2014. A novel role of the vacuolar calcium channel Yvc1 in stress response, morphogenesis and pathogenicity of *Candida albicans*. *Int. J. Med. Microbiol.* 304:339–50
208. Yu Q, Wang H, Xu N, Cheng X, Wang Y, et al. 2012. Spf1 strongly influences calcium homeostasis, hyphal development, biofilm formation and virulence in *Candida albicans*. *Microbiology* 158:2272–82
209. Zarnowski R, Westler WM, Lacmouh GA, Marita JM, Bothe JR, et al. 2014. Novel entries in a fungal biofilm matrix encyclopedia. *mBio* 5:e01333-14
210. Zeidler U, Bougnoux ME, Lupan A, Helynek O, Doyen A, et al. 2013. Synergy of the antibiotic colistin with echinocandin antifungals in *Candida* species. *J. Antimicrob. Chemother.* 68:1285–96
211. Zhang X, Sun X, Wang Z, Zhang Y, Hou W. 2012. Keratitis-associated fungi form biofilms with reduced antifungal drug susceptibility. *Invest. Ophthalmol. Visual Sci.* 53:7774–78
212. Zhao X, Daniels KJ, Oh SH, Green CB, Yeater KM, et al. 2006. *Candida albicans* Als3p is required for wild-type biofilm formation on silicone elastomer surfaces. *Microbiology* 152:2287–99
213. Zhao X, Oh SH, Yeater KM, Hoyer LL. 2005. Analysis of the *Candida albicans* Als2p and Als4p adhesins suggests the potential for compensatory function within the Als family. *Microbiology* 151:1619–30